聖諾醫藥-B(02257.HK):Francois Lebel辭任首席醫務官 葉永基辭任首席財務官
格隆匯6月3日丨聖諾醫藥-B(02257.HK)發佈公吿,以下事宜自2024年5月31日起生效:(i)由於Francois Lebel博士(“Lebel博士”)擬投放更多時間處理其他事務,已辭任集團首席醫務官一職。Lebel博士已同意出任集團藥物開發戰略事務的高級顧問。公司將尋求物色合適人選以填補首席醫務官的空缺。在此過渡期間,集團將聘請合約研究機構履行其臨牀開發職能;及(ii)由於葉永基先生擬投放更多時間處理其他事務,已辭任集團首席財務官一職。葉先生將繼續擔任集團企業交易相關事務的顧問。董事會信納,於葉先生辭任後,公司有足夠資源履行其戰略規劃、財務管理分析及內部控制職能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.